Loading... (0%)
About liver disease

GENFIT: A GLOBAL APPROACH TO THE DISEASE

Facilitate identification and referrals of NASH patients.
LEARN MORE
Phase 3 study of elafibranor in NASH with fibrosis is currently enrolling patients around the world.
LEARN MORE

COMPANY LIFE

GENFIT is a biopharmaceutical company dedicated to high unmet medical needs.
Learn more
Find out our about current job opportunities or submit your spontaneous application explaining your project.
LEARN MORE

DOCUMENTATION

The NASH Education Program™

Health prevention, medical education, dissemination of relevant information related to NASH disease

ACCESS THE NASH EDUCATION PROGRAM™ WEBSITE
News
  • Shareholders Letter
    N°8, October 2017
Press releases
  • GENFIT: Contributing Significantly to the European LITMUS Initiative on NASH Biomarkers
    11/27/2017
  • GENFIT: Positive Outcome from the 18-month Pre-Planned Safety Review by the DSMB, in RESOLVE-IT Phase 3 Clinical Trial with Elafibranor
    11/22/2017
  • GENFIT completes a €180 million offering of bonds convertible into new shares and/or exchangeable for existing shares (“OCEANEs”) due 2022
    10/17/2017
Events